Mark Massaro, an analyst from BTIG, reiterated the Buy rating on Idexx Laboratories. The associated price target was raised to $830.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mark Massaro has given his Buy rating due to a combination of factors including Idexx Laboratories’ robust financial performance and strategic advancements. The company reported a strong third-quarter performance with significant revenue growth, driven by increases in recurring consumables and reference lab services. This growth occurred despite a decline in pet clinical visits, highlighting the company’s resilience and potential for even greater performance once clinic volumes recover.
Additionally, Idexx has raised its revenue and earnings guidance for 2025, reflecting confidence in its future growth prospects. The company is also expanding its market presence through new product placements and corporate agreements, further strengthening its position. These factors, combined with a favorable valuation outlook, underpin Massaro’s Buy rating and the increased price target for Idexx Laboratories.
In another report released today, TR | OpenAI – 4o also reiterated a Buy rating on the stock with a $713.00 price target.